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EVIDENCE OF PREVENTION AND
TREATMENT OF POSTTHROMBOTIC
SYNDROME
—Robert B. McLafferty, MD, Springfield, Ill
Definition and affliction. Postthrombotic syndrome
(PTS) is a chronic condition that is made up of a constel-
lation of clinical signs and symptoms of the lower extremity
that develop after deep venous thrombosis (DVT). PTS
affects upward of 20% to 50% of patients after DVT and,
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tions of DVT.1-4 The number of patients afflicted with PTS
remains elusive due to the difficulties in accurately deter-
mining howmany patients develop DVT. Nevertheless, the
prevalence is thought to be increasing with 250,000 new
cases in the United States each year.5 Cumulative rates of
PTS have also been shown to increase after the diagnosis of
DVT. Mohr et al6 showed in a population-based study that
rates of PTS after DVT were 7% at 1 year, 14% at 5 years,
20% at 10 years, and 27% at 20 years. The cumulative rate of
ulcers by 20 years was 4%. Others have documented equally
devastating rates of PTS in longitudinal population-based
studies and a thorough review of North American and
European studies determining that the pooled incidence of
PTS after DVT was 46%, of which 15% developed an
ulcer.1,2,7 Equally important was the finding that the large
majority of patients develop PTS within 1 to 2 years.
Diagnosis. The diagnosis of PTS remains dependent
on having a varying degree of physical sequela and symp-
toms. These manifestations develop after the typical pain
and edema that occur for 3 to 6 months after resolution of
acute DVT. The Table gives an overview of these chronic
symptoms. Often the signs and symptoms of PTS will
worsen with activity and improve with rest and leg eleva-
tion. Additionally, PTS cannot be diagnosed in the absence
of clinical signs and symptoms. Some patients with a past
diagnosis of DVT can have abnormal venous valve function
with absent clinical signs and symptoms of PTS.8,9 Hence,
the criterion standard for the diagnosis depends on the past
diagnosis of DVT in combination with varying degrees of
the chronic clinical sequela.
Risk factors. A variety of risk factors have been iden-
tified that increase a patient’s likelihood of developing PTS.
In contrast, other factors which intuitively would be
thought to increase that likelihood have been found thus
far to be inconclusive. These risk factors, which will not be
discussed in this brief introduction, include but are not
limited to age, gender, thrombophilia, location of DVT,
residual thrombosis after anticoagulation, and lack of long-
term anticoagulation.
Table. Common signs and symptoms of postthrombotic
syndrome, which will often worsen with activity and
improve with leg elevation
Signs Symptoms
Pain Edema
Dull Telangiectasia
Aching Reticular veins
Lame Corona phlebetatica
Bursting Varicose veins
Warmth Redness
Heaviness Dermatitis
Tingling Cyanosis
Itching Hyperpigmentation
Cramps Lipodermatosclerosis
Atrophy blanch
Healed ulcerBy far, the most important risk factor in the develop-
ment of PTS is recurrent DVT in the previously affected
extremity. A number of studies have shown that the in-
crease in risk can be as high as 10-fold.1,7,10 Further dam-
age to already compromised venous valves and/or increas-
ing outflow obstruction are the presumed mechanisms.
Obesity, as measured by an increasing body mass index
(BMI), may also increase the risk of PTS. In one study of
symptomatic patients with proximal DVT who were fol-
lowed for 1 year, PTS developed at a significantly higher
rate in individuals with a higher BMI.11 Kahn et al12 also
demonstrated in a secondary analysis of a trial comparing
differing levels of anticoagulation for idiopathic proximal
DVT that a higher BMI was associated with an increasing
severity of PTS. A BMI of greater than 25 has also been
shown to be an independent predictor of PTS in patients
with proximal DVT.10
Patients found with the incidental findings of DVT and
lack of symptoms (asymptomatic DVT) may also be at risk of
developing PTS. One meta-analysis examining the results of
seven studies of patients diagnosed with asymptomatic DVT
in the postoperative period reported the relative risk of PTS to
be 1.6 (confidence interval [CI], 1.24-2.02) as compared to
similar patients without DVT.13 Patients undergoing total
knee or hip replacementwhodevelop asymptomaticDVTand
were treated with anticoagulation had significantly more per-
sistent edema compared to similar patients without DVT
(24% vs 1%).14 The question as to how these types of ortho-
pedic surgery “mask” a DVT in the postoperative period,
making it seem asymptomatic, still remains. Nevertheless, the
development of PTS in patients with no history ofDVT could
be explained by this phenomenon.
Pathophysiology. The large majority of patients
treated with anticoagulation for DVT continue to have
residual thrombus, thus resulting in few with return of
normal physiologic function.15,16 Moreover, even in the
setting of complete resolution of thrombus, there is often
permanent venous valve damage.17 It seems reasonable to
presume that the vigorousness of inflammation that accom-
panies DVT asserts permanent dysfunction to these dy-
namic and delicate valvular structures. This in combination
with incomplete thrombus resolution and strictures from
the inflammatory process also can lead to obstruction. The
end result is venous hypertension which then leads to
increased tissue permeability at the capillary level. The
exudation of proteins and red blood cells leads to a further
inflammatory response. Ultimately, this cascade of events, if
left untreated, can continue to progress to skin ischemia in
the perimalleolar region and ulceration.
EFFECTIVENESS OF PREVENTION AND
TREATMENT
Compression. The long-term use of graduated elastic
compression stockings (ECSs) in the prevention and treat-
ment of PTS has been examined by four trials. Brandjes et
al18 performed a randomized study on 194 patients with
symptomatic proximal vein thrombosis to either 30 to 40
mm Hg ECSs vs no-ECSs for at least 2 years. The effects
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20% and severe PTS decreasing from 23% to 11%. Similarly,
Prandoni et al7 examined the 2-year effectiveness of 30 to
40 mmHg ECSs vs no-ECSs in 180 patients with proximal
DVT. PTS was reduced from 49% to 26% using ECSs. In
contrast, a small randomized trial by Ginsberg et al19
showed no reduction in PTS using 20 to 30 mm Hg ECSs
vs sham stockings in patients who had no symptoms of PTS
1 year after proximal DVT. In this study, using ECSs or
sham stockings for up to 4 years, only 1 patient in the sham
group developed PTS. Amore recent study by Aschwanden
et al20 randomized 169 patients to 26 to 36 mmHG vs no
stockings 6 months after standard treatment for proximal
DVT. Proximal DVT was defined as acute primary or
recurrent thrombus involving the popliteal vein or more
proximal. With a mean follow-up of 3.2 years in the ECS
group and 2.9 years in the no-stocking group, 13.1% of the
ECS group developed CEAP classification 4 or greater,
whereas similar findings occurred in 20% of the no-stocking
group (hazard ratio [HR], 0.60; CI, 0.28-1.28; P  .19).
Five additional patients in the control group developed
PTS symptoms and required ECSs, which was not included
in the primary endpoint. Interestingly, although no signif-
icant differences were observed in men, women showed
significant reduction in the development of severe skin
changes with the use of ECSs (HR, 0.11; CI, 0.02-0.91).
Some of these gender differences could be attributed to
compliance in that men were four times more likely to be
noncompliant with ECSs (odds ratio [OR], 4.1; CI, 1.0-
16.0; P  .05). Further meta-analysis of the first three
studies (not including the Aschwanden et al20 study) found
that 30 to 40 mm Hg ECSs dramatically reduce the risk of
any PTS (OR, 0.3; 95% CI, 0.2-0.48) and severe PTS (OR,
0.39; 95% CI, 0.2-0.76).21 Hence, this has followed the
recommendation from the American College of Chest Phy-
sicians (ACCP) that 30 to 40mmHgECSs should be worn
for a minimum of 2 years (or longer depending on symp-
toms) in patients with a history of acute symptomatic
proximal DVT.22
Despite randomization in the aforementioned trials,
there are significant weaknesses, thus making the recom-
mendation to use ECSs to prevent and treat PTS less
generalizable. These weaknesses include small sample sizes,
single center studies, improper designation of placebo, and
most importantly lack of blinding to treatment group when
assessing for PTS in follow-up. With the exception of
moderate to severe arterial insufficiency, ECSs are unlikely
to cause harm to the lower extremities. Nevertheless, ECSs
are expensive, difficult to put on, uncomfortable for some,
and have significant wear and tear after 3 to 6 months.23
The currently underway SOX trial represents amajor step in
avoiding the weaknesses cited in the other studies.24 This
multicenter double-blind trial plans to randomize 800 pa-
tients to ECSs or inactive stockings to determine preven-
tion of PTS after 2 years of treatment. Until completion of
the SOX trial, a grade recommendation of “strong with
moderate evidence” seems warranted for the use of 30 to
40mmHgECSs in the prevention and treatment of PTS.25Catheter directed thrombolysis. The current guide-
lines from the ACCP recommend that catheter-directed or
pharmacomechanical thrombolysis be performed in se-
lected patients with iliofemoral DVT.22 Patients best suited
to benefit from these types of therapy include those with a
blood clot less than 14-days old, life expectancy greater
than 1 year with adequate functional status, and minimal
risk for bleeding complications. This represents a dramatic
change in recommendations from the ACCP guidelines 4
years prior of only performing catheter-directed thrombol-
ysis for limb-threatening ischemia from cerulea phlegmesia
dolens.26 Several studies have emerged in moving to rec-
ommend a more aggressive stance for iliofemoral DVT by
endovascular methods. Elsharawy et al27 performed a ran-
domized trial on 35 patients with iliofemoral DVT. Treat-
ment was catheter-directed pulse spray using streptokinase
vs standard anticoagulation. At 6-months follow-up, pa-
tency of the iliofemoral segment was 72% for the lysis group
and 12% for the anticoagulation group (P  .001). Addi-
tionally, valvular reflux was significantly higher in the anti-
coagulation group compared to the lysis group (41% vs
11%; P  .04). AbuRahma et al28 concluded in a small
non-randomized study that catheter-directed lysis/stent-
ing (n  18) was more effective in treating patients with
iliofemoral thrombosis than conventional anticoagulation
therapy (n  33). Primary patency of the iliofemoral ve-
nous segment at 1, 3, and 5 years were 83%, 69%, and 69%
for the lysis group and 24%, 18%, and 18% for the conser-
vative cohort, respectively. At 30 days, symptom relief was
obtained in only 1 patient (3%) in the conservative cohort
and 15 patients (83%) in the lysis group. Laiho et al,29 using
a hospital registry, identified 16 patients having catheter-
directed thrombolysis and 16 having systemic thromboly-
sis. Valvular competence was preserved significantly more
in the former group compared to the latter (44% vs 13%;
P  .049). Other studies, either registry or retrospective
cohorts, confirm added benefit from catheter-directed
thrombolysis of acute iliofemoral venous thrombosis, thus
conveying a grade recommendation of “strong with mod-
erate evidence” to it.25,30,31
Two multicenter randomized controlled trials are cur-
rently underway to address whether catheter-directed or phar-
macomechanical thrombolysis compared to anticoagulation
alone prevents formation of PTS. The CaVenT trial, ongoing
in Europe, has published preliminary 6-month data for treat-
ment of iliofemoral DVT that shows 64% patency for the lysis
group vs 36% patency in the anticoagulation group (P 
.004).32 Similarly, obstruction was present significantly more
often in the anticoagulation group compared to the lysis
group (49% vs 20%; P  .004). There were no differences in
femoral venous insufficiency. The ATTRACT trial is begin-
ning in theUnited States andCanada and will examine a wide
array of PTS outcomes after treatment of iliofemoral and/or
femoral-popliteal DVT.33
Other measures for prevention and treatment.
There are a number of other measures beyond the scope of
this review that can be implemented to prevent or treat PTS
after acute DVT. Prevention of recurrent ipsilateral DVT is
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Other measures include weight loss,10,12 administering
horse chestnut seed extract,34 performing venous angio-
plasty and stenting to treat obstruction,35 and surgical
repair or replacement of venous valves.36
COMMENT
PTS remains a serious long-term complication of DVT
with severely debilitating consequences for hundreds of
thousands of individuals. Although many factors play a role
in its development, physicians and scientists alike are begin-
ning to understand that PTS can be prevented and treated.
This brief summary outlined herein offers evidence of those
interventions that can be implemented with the hope of
relief. Nevertheless, more work and innovation are neces-
sary to stop the progression of PTS after DVT. Evidence
lacks for the majority of recommended treatments and a
coordinated worldwide effort is needed to build consensus,
educate physicians and the public, and implement best
evidence practices with cost consciousness.
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CRITICAL ISSUES IN PREVENTING POST-
THROMBOTIC RE-ULCERATION
—Peter Pappas, MD, Newark, NJ
The lack of effective therapies and the recurrent nature
of chronic venous insufficiency (CVI) place a heavy burden
on the United States healthcare system. The population-
based costs in the United States for treatment of CVI and
venous ulcer care has been estimated at over one billion
dollars a year. The high incidence and increasing cost of
CVI care has renewed interest in this disease process and
much has been learned in the past decade.
Primary valvular incompetence with or without obstruc-
tion causes ambulatory venous hypertension in the lower
extremity. Increased pressure is transmitted to the dermal
microcirculation resulting in extravasation or red blood cells
(RBCs) and macromolecules. RBCs and macromolecules
cause an injury to the dermal architecture resulting in micro-
circulatory activation of adhesion molecules and leukocyte
recruitment. Activated leukocytes in conjunction with in-
creased extra-cellular matrix tension may be the underlying
cause of venous ulcer formation.Recently publisheddata from
our laboratory indicates that CVI disease progression is asso-
ciated with increased fibroblast mediated contractile proper-
ties and a potential ability to accelerate venous ulcer healing. A
consequence of this adaptive wound healing response is in-
creased stored kinetic energy and tension in dermis of patients
with CVI. In our experiments, we observed gel contraction in
unstipulated gels indicating that fibroblasts surrounded by an
extracellular matrix, exert a baseline degree of tension on their
surrounding environment. This tension is increased when
stimulated with transforming growth factor-1 and/or extra-
cellular signal-regulated kinase inhibition. We believe that an
injury to the CVI dermal architecture releases stored kinetic
energy in the dermis and clinically manifests itself initially as
wound separation. This clinical situation is analogous to a
stretched rubber band. When external forces are used to
stretch a rubber band, tension is exerted on the elastic fibers
within the band.When the rubber band is released, the stored
kinetic energy within the elastic fibers is released and the band
contracts. It is clear that increased fibroblast contractility is
beneficial in healing wounds. However, in patients with der-
mal fibrosis and increasedmatrix tension, an injury that causes
architectural damage may be the underlying stimulus that
releases kinetic energy and causes initial wound separation.
If the above hypothesis is true, then it is logical to
assume that medical or surgical correction of venous hyper-
tension should prevent RBC and macromolecule extrava-
sation and stops the underlying inflammatory injury event.Given the fact that compression therapy is the mainstay of
venous ulcer healing, there seems to be credence to this
hypothesis. Therefore, one must assume that venous re-
ulceration is partially if not completely related to the per-
sistence of venous hypertension in primary CVI. In patients
with PTS, the effectiveness of clot resolution and anticoag-
ulation is another related factor.
PTS is the development of CVI after an episode of deep
venous thrombosis. Patients with PTS can manifest any of
the signs of the CVI from pain and edema to severe
lipodermatosclerosis and venous ulceration. Every clinical
venous study performed has indicated that PTS patients
have worse symptoms and higher venous ulcer recurrence
rates. Why the outcomes are poorer is currently unknown.
In a recent review by Prandoni in the British Journal of
Hematology a proximal venous thrombosis, previous ipsilat-
eral DVT, insufficient oral anticoagulation, and poor vein
recanalization after 6 months of anticoagulation were all
strong predictors for the development of PTS. Based upon
these facts, what are the current road blocks to preventing
re-ulceration in patients with PTS?
1. Pathophysiology of venous ulcer formation. Although
great progress has been made over the past 2 decades, the
pathophysiology of ulcer formation is still poorly under-
stood. Effective medical and surgical therapies cannot be
developed without a better understanding of how end
organ damage is caused by venous hypertension.
2. Ineffective anticoagulation andpoor venous recanalization
strongly suggest that lytic therapy may play a significant
role in decreasing the incidence of PTS. Presumably this
effect is secondary to valve function preservation and/or
the prevention of venous outflow obstruction. Random-
ized trials are currently being conducted to evaluate the
role of venous lysis in the prevention of PTS.
3. Wehave noobjectivemethodor good imaging techniques
for determining venous obstruction. Current data on sur-
gical valve repairs or valve transplants have all depended
heavily on the subjective assessment of vein patency based
on venography. Examination of excised, recanalized veins
have documented high-grade stenoses in damaged veins
despite their patent appearance on venography. To over-
come this road block, I suggest the following:
(a) Re-assess valve repair in conjunction with stenting
and/or endophlebectomy.
(b) Consider re-evaluating angioscopy as a method to
assess venous obstruction. Perhaps the angioscope
can be modified with a side port that can cut
endovenous scar tissue and widen lumen patency.
(c) Consider a natural history study using an intravas-
cular ultrasound scan to assess venous anatomy in
patients with PTS.
4. Compression therapy is currently the gold standard for
ulcer healing and recurrence. Despite this fact, ulcer
recurrence is still seen in compression patients for rea-
sons that are currently unknown. I propose the follow-
ing to overcome this roadblock:
